nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—ankylosing spondylitis	0.544	1	CbGaD
Pomalidomide—PTGS2—Sulfasalazine—ankylosing spondylitis	0.064	0.168	CbGbCtD
Pomalidomide—PTGS2—Triamcinolone—ankylosing spondylitis	0.064	0.168	CbGbCtD
Pomalidomide—PTGS2—Betamethasone—ankylosing spondylitis	0.0549	0.144	CbGbCtD
Pomalidomide—PTGS2—Dexamethasone—ankylosing spondylitis	0.032	0.0836	CbGbCtD
Pomalidomide—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0279	0.0729	CbGbCtD
Pomalidomide—ABCB1—Betamethasone—ankylosing spondylitis	0.0181	0.0474	CbGbCtD
Pomalidomide—ABCB1—Prednisolone—ankylosing spondylitis	0.0179	0.0468	CbGbCtD
Pomalidomide—ABCB1—Prednisone—ankylosing spondylitis	0.0169	0.0442	CbGbCtD
Pomalidomide—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0167	0.0437	CbGbCtD
Pomalidomide—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0127	0.0331	CbGbCtD
Pomalidomide—CYP3A4—Betamethasone—ankylosing spondylitis	0.0109	0.0284	CbGbCtD
Pomalidomide—CYP3A4—Prednisolone—ankylosing spondylitis	0.0107	0.028	CbGbCtD
Pomalidomide—ABCB1—Dexamethasone—ankylosing spondylitis	0.0105	0.0276	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—ankylosing spondylitis	0.0101	0.0265	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—ankylosing spondylitis	0.00847	0.0222	CbGbCtD
Pomalidomide—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00632	0.0165	CbGbCtD
Pomalidomide—Thalidomide—TNF—ankylosing spondylitis	0.00263	1	CrCbGaD
Pomalidomide—TNF—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.00217	0.109	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.00143	0.0718	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL17A—ankylosing spondylitis	0.000757	0.0379	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL12B—ankylosing spondylitis	0.000704	0.0352	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL12B—ankylosing spondylitis	0.000683	0.0342	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.000581	0.0291	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.000571	0.0286	CbGpPWpGaD
Pomalidomide—TNF—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000556	0.0278	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —TNFRSF1B—ankylosing spondylitis	0.000538	0.0269	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.000531	0.0266	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL1A—ankylosing spondylitis	0.000502	0.0251	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL10—ankylosing spondylitis	0.000499	0.025	CbGpPWpGaD
Pomalidomide—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.000497	0.159	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.000489	0.156	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.000489	0.156	CbGdCrCtD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.000488	0.0244	CbGpPWpGaD
Pomalidomide—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000478	0.153	CbGdCrCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000446	0.0223	CbGpPWpGaD
Pomalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000424	0.0212	CbGpPWpGaD
Pomalidomide—Febrile neutropenia—Methotrexate—ankylosing spondylitis	0.000421	0.00867	CcSEcCtD
Pomalidomide—Deep vein thrombosis—Methotrexate—ankylosing spondylitis	0.000416	0.00858	CcSEcCtD
Pomalidomide—Embolism—Methotrexate—ankylosing spondylitis	0.000394	0.00813	CcSEcCtD
Pomalidomide—Neuropathy—Prednisolone—ankylosing spondylitis	0.000391	0.00807	CcSEcCtD
Pomalidomide—Neuropathy—Triamcinolone—ankylosing spondylitis	0.00036	0.00742	CcSEcCtD
Pomalidomide—Neuropathy—Methylprednisolone—ankylosing spondylitis	0.000359	0.0074	CcSEcCtD
Pomalidomide—Interstitial lung disease—Methotrexate—ankylosing spondylitis	0.000357	0.00737	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—IL1A—ankylosing spondylitis	0.000353	0.0177	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000344	0.0172	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000342	0.0171	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00034	0.017	CbGpPWpGaD
Pomalidomide—Cardiac failure congestive—Prednisolone—ankylosing spondylitis	0.000334	0.00688	CcSEcCtD
Pomalidomide—TNF—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.000332	0.0166	CbGpPWpGaD
Pomalidomide—Neuropathy—Dexamethasone—ankylosing spondylitis	0.000326	0.00673	CcSEcCtD
Pomalidomide—Neuropathy—Betamethasone—ankylosing spondylitis	0.000326	0.00673	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL17A—ankylosing spondylitis	0.000311	0.0156	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.000309	0.0155	CbGpPWpGaD
Pomalidomide—Cardiac failure congestive—Triamcinolone—ankylosing spondylitis	0.000307	0.00632	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Methylprednisolone—ankylosing spondylitis	0.000306	0.00631	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000305	0.0153	CbGpPWpGaD
Pomalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.0003	0.0957	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	0.000295	0.0942	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	0.000295	0.0942	CbGdCrCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.000292	0.0146	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL12B—ankylosing spondylitis	0.000289	0.0145	CbGpPWpGaD
Pomalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	0.000288	0.0921	CbGdCrCtD
Pomalidomide—Neuropathy—Prednisone—ankylosing spondylitis	0.000284	0.00586	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Betamethasone—ankylosing spondylitis	0.000278	0.00574	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Dexamethasone—ankylosing spondylitis	0.000278	0.00574	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Methotrexate—ankylosing spondylitis	0.000278	0.00574	CcSEcCtD
Pomalidomide—Dry skin—Prednisolone—ankylosing spondylitis	0.000277	0.00572	CcSEcCtD
Pomalidomide—Muscular weakness—Prednisolone—ankylosing spondylitis	0.000267	0.0055	CcSEcCtD
Pomalidomide—Sepsis—Prednisone—ankylosing spondylitis	0.000263	0.00542	CcSEcCtD
Pomalidomide—Pulmonary embolism—Methotrexate—ankylosing spondylitis	0.000253	0.00522	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.000252	0.0126	CbGpPWpGaD
Pomalidomide—Breast disorder—Methylprednisolone—ankylosing spondylitis	0.000251	0.00517	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000249	0.0124	CbGpPWpGaD
Pomalidomide—Muscular weakness—Triamcinolone—ankylosing spondylitis	0.000245	0.00506	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.000245	0.00505	CcSEcCtD
Pomalidomide—Muscular weakness—Methylprednisolone—ankylosing spondylitis	0.000245	0.00505	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Methotrexate—ankylosing spondylitis	0.000244	0.00504	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Prednisone—ankylosing spondylitis	0.000242	0.005	CcSEcCtD
Pomalidomide—Weight increased—Prednisolone—ankylosing spondylitis	0.000238	0.0049	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000236	0.0118	CbGpPWpGaD
Pomalidomide—Dry skin—Betamethasone—ankylosing spondylitis	0.000231	0.00477	CcSEcCtD
Pomalidomide—Dry skin—Dexamethasone—ankylosing spondylitis	0.000231	0.00477	CcSEcCtD
Pomalidomide—Bronchitis—Triamcinolone—ankylosing spondylitis	0.000231	0.00477	CcSEcCtD
Pomalidomide—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.00023	0.00474	CcSEcCtD
Pomalidomide—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.00023	0.00474	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Prednisolone—ankylosing spondylitis	0.000228	0.00471	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Triamcinolone—ankylosing spondylitis	0.000223	0.00461	CcSEcCtD
Pomalidomide—Muscular weakness—Dexamethasone—ankylosing spondylitis	0.000223	0.00459	CcSEcCtD
Pomalidomide—Muscular weakness—Betamethasone—ankylosing spondylitis	0.000223	0.00459	CcSEcCtD
Pomalidomide—Sepsis—Methotrexate—ankylosing spondylitis	0.00022	0.00453	CcSEcCtD
Pomalidomide—Weight increased—Triamcinolone—ankylosing spondylitis	0.000219	0.00451	CcSEcCtD
Pomalidomide—Weight increased—Methylprednisolone—ankylosing spondylitis	0.000218	0.0045	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000215	0.0108	CbGpPWpGaD
Pomalidomide—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000214	0.00441	CcSEcCtD
Pomalidomide—Infestation—Methylprednisolone—ankylosing spondylitis	0.000214	0.00441	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL1A—ankylosing spondylitis	0.000213	0.0106	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000212	0.0106	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL10—ankylosing spondylitis	0.000212	0.0106	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Triamcinolone—ankylosing spondylitis	0.00021	0.00433	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Methylprednisolone—ankylosing spondylitis	0.00021	0.00432	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—CRP—ankylosing spondylitis	0.000205	0.0103	CbGpPWpGaD
Pomalidomide—Epistaxis—Triamcinolone—ankylosing spondylitis	0.000202	0.00417	CcSEcCtD
Pomalidomide—Dry skin—Prednisone—ankylosing spondylitis	0.000201	0.00415	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000201	0.0101	CbGpPWpGaD
Pomalidomide—Hypokalaemia—Prednisone—ankylosing spondylitis	0.0002	0.00412	CcSEcCtD
Pomalidomide—Weight increased—Dexamethasone—ankylosing spondylitis	0.000199	0.00409	CcSEcCtD
Pomalidomide—Weight increased—Betamethasone—ankylosing spondylitis	0.000199	0.00409	CcSEcCtD
Pomalidomide—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000197	0.00407	CcSEcCtD
Pomalidomide—Weight decreased—Betamethasone—ankylosing spondylitis	0.000197	0.00407	CcSEcCtD
Pomalidomide—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.000197	0.00406	CcSEcCtD
Pomalidomide—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.000197	0.00406	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000194	0.004	CcSEcCtD
Pomalidomide—Muscular weakness—Prednisone—ankylosing spondylitis	0.000194	0.004	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Dexamethasone—ankylosing spondylitis	0.000191	0.00393	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Betamethasone—ankylosing spondylitis	0.000191	0.00393	CcSEcCtD
Pomalidomide—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000189	0.00389	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000189	0.00944	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000186	0.00933	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000184	0.00921	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000178	0.00367	CcSEcCtD
Pomalidomide—Neutropenia—Prednisone—ankylosing spondylitis	0.000178	0.00366	CcSEcCtD
Pomalidomide—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000174	0.00359	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000173	0.00357	CcSEcCtD
Pomalidomide—Weight increased—Prednisone—ankylosing spondylitis	0.000173	0.00356	CcSEcCtD
Pomalidomide—Weight decreased—Prednisone—ankylosing spondylitis	0.000172	0.00354	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000172	0.00858	CbGpPWpGaD
Pomalidomide—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.000171	0.00353	CcSEcCtD
Pomalidomide—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000168	0.00347	CcSEcCtD
Pomalidomide—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000167	0.00345	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.000166	0.00342	CcSEcCtD
Pomalidomide—Breast disorder—Methotrexate—ankylosing spondylitis	0.000166	0.00342	CcSEcCtD
Pomalidomide—Vertigo—Prednisolone—ankylosing spondylitis	0.000164	0.00337	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000163	0.00817	CbGpPWpGaD
Pomalidomide—Back pain—Triamcinolone—ankylosing spondylitis	0.000162	0.00334	CcSEcCtD
Pomalidomide—Angiopathy—Betamethasone—ankylosing spondylitis	0.000158	0.00327	CcSEcCtD
Pomalidomide—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000158	0.00327	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000156	0.00781	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000156	0.00779	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000154	0.00772	CbGpPWpGaD
Pomalidomide—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000151	0.00311	CcSEcCtD
Pomalidomide—Vertigo—Triamcinolone—ankylosing spondylitis	0.00015	0.0031	CcSEcCtD
Pomalidomide—Vertigo—Methylprednisolone—ankylosing spondylitis	0.00015	0.0031	CcSEcCtD
Pomalidomide—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000149	0.00308	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000149	0.00747	CbGpPWpGaD
Pomalidomide—Neutropenia—Methotrexate—ankylosing spondylitis	0.000148	0.00306	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000148	0.00304	CcSEcCtD
Pomalidomide—Cough—Triamcinolone—ankylosing spondylitis	0.000146	0.00301	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000144	0.00296	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—ankylosing spondylitis	0.000142	0.00294	CcSEcCtD
Pomalidomide—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000142	0.00293	CcSEcCtD
Pomalidomide—Anxiety—Methylprednisolone—ankylosing spondylitis	0.000142	0.00292	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—ankylosing spondylitis	0.000142	0.00292	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000142	0.00292	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000141	0.00291	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—ankylosing spondylitis	0.000139	0.00287	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000139	0.00696	CbGpPWpGaD
Pomalidomide—Angiopathy—Prednisone—ankylosing spondylitis	0.000138	0.00284	CcSEcCtD
Pomalidomide—Confusional state—Methylprednisolone—ankylosing spondylitis	0.000138	0.00284	CcSEcCtD
Pomalidomide—Vertigo—Betamethasone—ankylosing spondylitis	0.000137	0.00282	CcSEcCtD
Pomalidomide—Vertigo—Dexamethasone—ankylosing spondylitis	0.000137	0.00282	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.000136	0.00683	CbGpPWpGaD
Pomalidomide—Infection—Triamcinolone—ankylosing spondylitis	0.000136	0.0028	CcSEcCtD
Pomalidomide—Infection—Methylprednisolone—ankylosing spondylitis	0.000136	0.00279	CcSEcCtD
Pomalidomide—Insomnia—Prednisolone—ankylosing spondylitis	0.000134	0.00277	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000134	0.00276	CcSEcCtD
Pomalidomide—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000134	0.00276	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—ankylosing spondylitis	0.000134	0.00275	CcSEcCtD
Pomalidomide—Mental disorder—Prednisone—ankylosing spondylitis	0.000133	0.00275	CcSEcCtD
Pomalidomide—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000132	0.00273	CcSEcCtD
Pomalidomide—Malnutrition—Prednisone—ankylosing spondylitis	0.000132	0.00273	CcSEcCtD
Pomalidomide—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000132	0.00272	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000132	0.00272	CcSEcCtD
Pomalidomide—Anxiety—Dexamethasone—ankylosing spondylitis	0.000129	0.00266	CcSEcCtD
Pomalidomide—Anxiety—Betamethasone—ankylosing spondylitis	0.000129	0.00266	CcSEcCtD
Pomalidomide—Pain—Prednisolone—ankylosing spondylitis	0.000127	0.00262	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.000127	0.00635	CbGpPWpGaD
Pomalidomide—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000125	0.00259	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000125	0.00257	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000125	0.00257	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000124	0.00256	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000124	0.00619	CbGpPWpGaD
Pomalidomide—Insomnia—Triamcinolone—ankylosing spondylitis	0.000124	0.00255	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000123	0.00618	CbGpPWpGaD
Pomalidomide—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000123	0.00254	CcSEcCtD
Pomalidomide—Infection—Dexamethasone—ankylosing spondylitis	0.000123	0.00254	CcSEcCtD
Pomalidomide—Infection—Betamethasone—ankylosing spondylitis	0.000123	0.00254	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000123	0.00614	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000122	0.00253	CcSEcCtD
Pomalidomide—Anaemia—Prednisone—ankylosing spondylitis	0.000122	0.00252	CcSEcCtD
Pomalidomide—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000122	0.00251	CcSEcCtD
Pomalidomide—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000122	0.00251	CcSEcCtD
Pomalidomide—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000122	0.00251	CcSEcCtD
Pomalidomide—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000121	0.0025	CcSEcCtD
Pomalidomide—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000121	0.0025	CcSEcCtD
Pomalidomide—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.00012	0.00247	CcSEcCtD
Pomalidomide—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.00012	0.00247	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—ankylosing spondylitis	0.000119	0.00245	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000118	0.00243	CcSEcCtD
Pomalidomide—Fatigue—Triamcinolone—ankylosing spondylitis	0.000118	0.00243	CcSEcCtD
Pomalidomide—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000118	0.00242	CcSEcCtD
Pomalidomide—Pain—Triamcinolone—ankylosing spondylitis	0.000117	0.00241	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000116	0.00582	CbGpPWpGaD
Pomalidomide—Angiopathy—Methotrexate—ankylosing spondylitis	0.000115	0.00238	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000115	0.00236	CcSEcCtD
Pomalidomide—Chills—Methotrexate—ankylosing spondylitis	0.000114	0.00235	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000113	0.00233	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000113	0.00233	CcSEcCtD
Pomalidomide—Arthralgia—Prednisone—ankylosing spondylitis	0.000113	0.00232	CcSEcCtD
Pomalidomide—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000113	0.00232	CcSEcCtD
Pomalidomide—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000112	0.00232	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—ankylosing spondylitis	0.000112	0.00232	CcSEcCtD
Pomalidomide—Insomnia—Betamethasone—ankylosing spondylitis	0.000112	0.00231	CcSEcCtD
Pomalidomide—Insomnia—Dexamethasone—ankylosing spondylitis	0.000112	0.00231	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000112	0.00231	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—ankylosing spondylitis	0.000111	0.0023	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—ankylosing spondylitis	0.000111	0.00228	CcSEcCtD
Pomalidomide—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00011	0.00226	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000109	0.00543	CbGpPWpGaD
Pomalidomide—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000108	0.00223	CcSEcCtD
Pomalidomide—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000108	0.00222	CcSEcCtD
Pomalidomide—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000108	0.00222	CcSEcCtD
Pomalidomide—Infection—Prednisone—ankylosing spondylitis	0.000107	0.00221	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000107	0.00221	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000107	0.00221	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—ankylosing spondylitis	0.000107	0.00221	CcSEcCtD
Pomalidomide—Fatigue—Dexamethasone—ankylosing spondylitis	0.000107	0.0022	CcSEcCtD
Pomalidomide—Fatigue—Betamethasone—ankylosing spondylitis	0.000107	0.0022	CcSEcCtD
Pomalidomide—Pain—Betamethasone—ankylosing spondylitis	0.000106	0.00219	CcSEcCtD
Pomalidomide—Pain—Dexamethasone—ankylosing spondylitis	0.000106	0.00219	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000106	0.00218	CcSEcCtD
Pomalidomide—Skin disorder—Prednisone—ankylosing spondylitis	0.000105	0.00216	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000104	0.00215	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—ankylosing spondylitis	0.000102	0.00211	CcSEcCtD
Pomalidomide—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000102	0.00211	CcSEcCtD
Pomalidomide—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000102	0.00211	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000101	0.00505	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000101	0.00208	CcSEcCtD
Pomalidomide—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.0001	0.00207	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—ankylosing spondylitis	9.94e-05	0.00205	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—ankylosing spondylitis	9.9e-05	0.00204	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	9.84e-05	0.00203	CcSEcCtD
Pomalidomide—Dizziness—Prednisolone—ankylosing spondylitis	9.83e-05	0.00203	CcSEcCtD
Pomalidomide—Asthenia—Triamcinolone—ankylosing spondylitis	9.81e-05	0.00202	CcSEcCtD
Pomalidomide—Body temperature increased—Betamethasone—ankylosing spondylitis	9.81e-05	0.00202	CcSEcCtD
Pomalidomide—Body temperature increased—Dexamethasone—ankylosing spondylitis	9.81e-05	0.00202	CcSEcCtD
Pomalidomide—Asthenia—Methylprednisolone—ankylosing spondylitis	9.79e-05	0.00202	CcSEcCtD
Pomalidomide—Insomnia—Prednisone—ankylosing spondylitis	9.77e-05	0.00201	CcSEcCtD
Pomalidomide—Pruritus—Triamcinolone—ankylosing spondylitis	9.67e-05	0.00199	CcSEcCtD
Pomalidomide—Cough—Methotrexate—ankylosing spondylitis	9.65e-05	0.00199	CcSEcCtD
Pomalidomide—Pruritus—Methylprednisolone—ankylosing spondylitis	9.65e-05	0.00199	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1A—ankylosing spondylitis	9.55e-05	0.00478	CbGpPWpGaD
Pomalidomide—Arthralgia—Methotrexate—ankylosing spondylitis	9.42e-05	0.00194	CcSEcCtD
Pomalidomide—Decreased appetite—Prednisone—ankylosing spondylitis	9.39e-05	0.00194	CcSEcCtD
Pomalidomide—Rash—Prednisolone—ankylosing spondylitis	9.37e-05	0.00193	CcSEcCtD
Pomalidomide—Dermatitis—Prednisolone—ankylosing spondylitis	9.36e-05	0.00193	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	9.35e-05	0.00193	CcSEcCtD
Pomalidomide—Diarrhoea—Methylprednisolone—ankylosing spondylitis	9.33e-05	0.00192	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	9.33e-05	0.00467	CbGpPWpGaD
Pomalidomide—Fatigue—Prednisone—ankylosing spondylitis	9.31e-05	0.00192	CcSEcCtD
Pomalidomide—Headache—Prednisolone—ankylosing spondylitis	9.31e-05	0.00192	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	9.27e-05	0.00464	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	9.27e-05	0.00464	CbGpPWpGaD
Pomalidomide—Constipation—Prednisone—ankylosing spondylitis	9.24e-05	0.0019	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—ankylosing spondylitis	9.1e-05	0.00188	CcSEcCtD
Pomalidomide—Dizziness—Triamcinolone—ankylosing spondylitis	9.04e-05	0.00186	CcSEcCtD
Pomalidomide—Dizziness—Methylprednisolone—ankylosing spondylitis	9.02e-05	0.00186	CcSEcCtD
Pomalidomide—Infection—Methotrexate—ankylosing spondylitis	8.97e-05	0.00185	CcSEcCtD
Pomalidomide—Feeling abnormal—Prednisone—ankylosing spondylitis	8.9e-05	0.00184	CcSEcCtD
Pomalidomide—Asthenia—Betamethasone—ankylosing spondylitis	8.9e-05	0.00183	CcSEcCtD
Pomalidomide—Asthenia—Dexamethasone—ankylosing spondylitis	8.9e-05	0.00183	CcSEcCtD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	8.86e-05	0.00443	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Methotrexate—ankylosing spondylitis	8.85e-05	0.00183	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—ankylosing spondylitis	8.84e-05	0.00182	CcSEcCtD
Pomalidomide—Nausea—Prednisolone—ankylosing spondylitis	8.83e-05	0.00182	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	8.82e-05	0.00441	CbGpPWpGaD
Pomalidomide—Pruritus—Betamethasone—ankylosing spondylitis	8.78e-05	0.00181	CcSEcCtD
Pomalidomide—Pruritus—Dexamethasone—ankylosing spondylitis	8.78e-05	0.00181	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—ankylosing spondylitis	8.77e-05	0.00181	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—ankylosing spondylitis	8.73e-05	0.0018	CcSEcCtD
Pomalidomide—Vomiting—Triamcinolone—ankylosing spondylitis	8.69e-05	0.00179	CcSEcCtD
Pomalidomide—Vomiting—Methylprednisolone—ankylosing spondylitis	8.67e-05	0.00179	CcSEcCtD
Pomalidomide—Rash—Triamcinolone—ankylosing spondylitis	8.62e-05	0.00178	CcSEcCtD
Pomalidomide—Dermatitis—Triamcinolone—ankylosing spondylitis	8.61e-05	0.00178	CcSEcCtD
Pomalidomide—Rash—Methylprednisolone—ankylosing spondylitis	8.6e-05	0.00177	CcSEcCtD
Pomalidomide—Dermatitis—Methylprednisolone—ankylosing spondylitis	8.59e-05	0.00177	CcSEcCtD
Pomalidomide—Headache—Triamcinolone—ankylosing spondylitis	8.56e-05	0.00177	CcSEcCtD
Pomalidomide—Headache—Methylprednisolone—ankylosing spondylitis	8.54e-05	0.00176	CcSEcCtD
Pomalidomide—Body temperature increased—Prednisone—ankylosing spondylitis	8.54e-05	0.00176	CcSEcCtD
Pomalidomide—Diarrhoea—Betamethasone—ankylosing spondylitis	8.49e-05	0.00175	CcSEcCtD
Pomalidomide—Diarrhoea—Dexamethasone—ankylosing spondylitis	8.49e-05	0.00175	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	8.22e-05	0.0017	CcSEcCtD
Pomalidomide—Dizziness—Betamethasone—ankylosing spondylitis	8.2e-05	0.00169	CcSEcCtD
Pomalidomide—Dizziness—Dexamethasone—ankylosing spondylitis	8.2e-05	0.00169	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	8.17e-05	0.00409	CbGpPWpGaD
Pomalidomide—Insomnia—Methotrexate—ankylosing spondylitis	8.17e-05	0.00168	CcSEcCtD
Pomalidomide—Nausea—Triamcinolone—ankylosing spondylitis	8.12e-05	0.00167	CcSEcCtD
Pomalidomide—Nausea—Methylprednisolone—ankylosing spondylitis	8.1e-05	0.00167	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—ankylosing spondylitis	8.05e-05	0.00166	CcSEcCtD
Pomalidomide—Hypersensitivity—Prednisone—ankylosing spondylitis	7.96e-05	0.00164	CcSEcCtD
Pomalidomide—Vomiting—Betamethasone—ankylosing spondylitis	7.89e-05	0.00163	CcSEcCtD
Pomalidomide—Vomiting—Dexamethasone—ankylosing spondylitis	7.89e-05	0.00163	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—ankylosing spondylitis	7.85e-05	0.00162	CcSEcCtD
Pomalidomide—Rash—Betamethasone—ankylosing spondylitis	7.82e-05	0.00161	CcSEcCtD
Pomalidomide—Rash—Dexamethasone—ankylosing spondylitis	7.82e-05	0.00161	CcSEcCtD
Pomalidomide—Dermatitis—Betamethasone—ankylosing spondylitis	7.81e-05	0.00161	CcSEcCtD
Pomalidomide—Dermatitis—Dexamethasone—ankylosing spondylitis	7.81e-05	0.00161	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	7.79e-05	0.00161	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—ankylosing spondylitis	7.78e-05	0.0016	CcSEcCtD
Pomalidomide—Headache—Dexamethasone—ankylosing spondylitis	7.77e-05	0.0016	CcSEcCtD
Pomalidomide—Headache—Betamethasone—ankylosing spondylitis	7.77e-05	0.0016	CcSEcCtD
Pomalidomide—Asthenia—Prednisone—ankylosing spondylitis	7.75e-05	0.0016	CcSEcCtD
Pomalidomide—Pain—Methotrexate—ankylosing spondylitis	7.72e-05	0.00159	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	7.68e-05	0.00384	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TLR4—ankylosing spondylitis	7.65e-05	0.00383	CbGpPWpGaD
Pomalidomide—Pruritus—Prednisone—ankylosing spondylitis	7.64e-05	0.00158	CcSEcCtD
Pomalidomide—Feeling abnormal—Methotrexate—ankylosing spondylitis	7.44e-05	0.00153	CcSEcCtD
Pomalidomide—Diarrhoea—Prednisone—ankylosing spondylitis	7.39e-05	0.00152	CcSEcCtD
Pomalidomide—Nausea—Dexamethasone—ankylosing spondylitis	7.37e-05	0.00152	CcSEcCtD
Pomalidomide—Nausea—Betamethasone—ankylosing spondylitis	7.37e-05	0.00152	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	7.18e-05	0.00359	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisone—ankylosing spondylitis	7.14e-05	0.00147	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—ankylosing spondylitis	7.14e-05	0.00147	CcSEcCtD
Pomalidomide—Vomiting—Prednisone—ankylosing spondylitis	6.87e-05	0.00142	CcSEcCtD
Pomalidomide—Rash—Prednisone—ankylosing spondylitis	6.81e-05	0.0014	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—ankylosing spondylitis	6.8e-05	0.0014	CcSEcCtD
Pomalidomide—Headache—Prednisone—ankylosing spondylitis	6.77e-05	0.0014	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—ankylosing spondylitis	6.65e-05	0.00137	CcSEcCtD
Pomalidomide—Asthenia—Methotrexate—ankylosing spondylitis	6.48e-05	0.00134	CcSEcCtD
Pomalidomide—Nausea—Prednisone—ankylosing spondylitis	6.42e-05	0.00132	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—ankylosing spondylitis	6.39e-05	0.00132	CcSEcCtD
Pomalidomide—Diarrhoea—Methotrexate—ankylosing spondylitis	6.18e-05	0.00127	CcSEcCtD
Pomalidomide—Dizziness—Methotrexate—ankylosing spondylitis	5.97e-05	0.00123	CcSEcCtD
Pomalidomide—Vomiting—Methotrexate—ankylosing spondylitis	5.74e-05	0.00118	CcSEcCtD
Pomalidomide—Rash—Methotrexate—ankylosing spondylitis	5.69e-05	0.00117	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—ankylosing spondylitis	5.69e-05	0.00117	CcSEcCtD
Pomalidomide—Headache—Methotrexate—ankylosing spondylitis	5.66e-05	0.00117	CcSEcCtD
Pomalidomide—Nausea—Methotrexate—ankylosing spondylitis	5.36e-05	0.00111	CcSEcCtD
Pomalidomide—PTGS2—Disease—ANTXR2—ankylosing spondylitis	5.3e-05	0.00265	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—ankylosing spondylitis	4.57e-05	0.00229	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	4.34e-05	0.00217	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	4.34e-05	0.00217	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—ankylosing spondylitis	3.61e-05	0.00181	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	3.53e-05	0.00177	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—B3GNT2—ankylosing spondylitis	3.12e-05	0.00156	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—B3GNT2—ankylosing spondylitis	2.62e-05	0.00131	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.46e-05	0.00123	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	1.85e-05	0.000928	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	1.74e-05	0.000872	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	1.48e-05	0.000741	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HLA-A—ankylosing spondylitis	1.26e-05	0.000632	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	1.14e-05	0.000572	CbGpPWpGaD
